Dendritic Cell Vaccine for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are on investigational agents or systemic immunosuppressants, you may not be eligible to participate.
What data supports the effectiveness of the dendritic cell vaccine treatment for breast cancer?
Is the dendritic cell vaccine generally safe for humans?
How is the dendritic cell vaccine treatment for breast cancer different from other treatments?
The dendritic cell vaccine for breast cancer is unique because it uses the patient's own immune cells, called dendritic cells, to create a personalized treatment that trains the immune system to attack cancer cells. This approach aims to enhance the body's natural ability to fight cancer, unlike conventional treatments that often involve chemotherapy or radiation, which can have significant side effects.12368
What is the purpose of this trial?
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Research Team
Hatem Soliman, MD
Principal Investigator
Moffitt Cancer Center
Eligibility Criteria
This trial is for individuals with a high-risk type of breast cancer known as TNBC, who have already undergone initial chemotherapy. Participants should be those whose tumors still remain after this treatment and are willing to undergo further procedures to create a personalized vaccine.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a personalized dendritic cell vaccine based on whole exome sequencing data of their residual breast tumor
Follow-up
Participants are monitored for safety, immunogenicity, and disease-free survival after treatment
Treatment Details
Interventions
- Dendritic Cell (DC) Vaccine
Dendritic Cell (DC) Vaccine is already approved in United States, European Union for the following indications:
- Triple-Negative Breast Cancer (TNBC)
- HER2+ Breast Cancer
- Leptomeningeal Disease
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor